Shots:
- BI has launched Vaxxitek HVT+IBD+H5, a trivalent poultry vaccine against marek’s disease, infectious bursal disease & H5 avian influenza; commercially available in Egypt by Feb 2025
- Trivalent vaccine uses BI’s COBRA tech to create unique antigen for protection against prevalent H5 clades & is administered at the hatchery for early chick protection to avoid immunity gaps between low maternal Abs & increased active immunity due to vaccination
- The vaccine is manufactured & licensed in the US since 2023; however, avian influenza vaccination is currently not permitted in the US
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
